Standigm

Standigm Applies Cutting-Edge AI Technology to Drug Discovery: AI and Biology Experts Collaborate to Build a Real-World AI Model for the Pharmaceutical Industry; Currently, the Company Focuses on Predicting New Indications for Existing Drugs Through an AI Model Deeply Trained with Molecular Characteristics of Drug Response and Usage for Drug Repositioning; Standigm Has Generated Dozens of Candidate Drugs for Cancer, Parkinson’s Disease (PD), Autism, and Nonalcoholic Steatohepatitis (NASH), Delivering Tangible Benefits in Time and Cost for the Pharmaceutical Industry by Eliminating Certain Uncertainties in the Drug Development Process.